Market Research Logo

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

The global liquid biopsy market should reach nearly $4.5 billion in 2020 from $1.6 billion in 2015, registering a CAGR of 22.3% for the period of 2015-2020.

This report provides:
An overview of the global markets for liquid biopsy research tools, services, and diagnostics
Analyses of global market trends, with data for 2014, estimates for 2015, and projections of CAGRs through 2020
Coverage of how these technologies can reduce invasive tumor biopsies, drive early cancer detection, and support precise drug administration
Detailed analysis of liquid biopsy workflow technologies, biomarker classes, sample types, research tools reagents, and more
Breakdowns of the market by product, product type, application, end use industry, technology, indication, as well as many others
Evaluation of the market's dynamics, specifically growth drivers, restraints, and opportunities
Profiles of major players in the industr


SCOPE AND FORMAT

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2014, 2015 and 2020.

This report reviews liquid biopsy biomarkers and technologies, and provides background on why liquid biopsy is advantageous versus tissue biopsy. It then discusses some of the top research initiatives that are contributing to liquid biopsy development. Market driving forces are also discussed.

The structure of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from 2013 to the present. Industry subsectors analyzed include NGS instruments, droplet digital PCR, target enrichment and amplification, single cell DNA polymerase, noninvasive prenatal screening and general liquid biopsy.

The market for liquid biopsy diagnostics is analyzed in depth. It covers commercialized diagnostic tests. The pure research field is excluded. The market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region, including North America, Europe, Asia-Pacific and the rest of the world.

Applications in this report include PCR-based, NGS-based, others (microarray, cytometry, Sanger sequencing, fluorescent in situ hybridization (FISH), and immunohistochemistry (IHC)).

Biomarker types in this report include cfDNA, CTC and EV.

Therapuetic areas in this report include cancer, NIPT and transplant.

Market data covers the years 2014, 2015 and 2020.

More than 85 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2013 through 2015, including key alliance trends.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
CONTRIBUTION OF THE STUDY AND FOR WHOM
SCOPE AND FORMAT
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
SUMMARY TABLE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, THROUGH 2020 ($ MILLIONS)
SUMMARY FIGURE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, 2014-2020 ($ MILLIONS)
CHAPTER 3 OVERVIEW
INTRODUCTION
TABLE 1 LIQUID BIOPSY SAMPLE TYPES
REPORT SCOPE
TABLE 2 LIQUID BIOPSY REPORT SCOPE
LIQUID BIOPSY VERSUS TRADITIONAL BIOPSY
MARKETS
TABLE 3 LIQUID BIOPSY MARKET BY ANALYSIS TYPE, THROUGH 2020 ($ MILLIONS)
GROWTH DRIVING FORCES
TABLE 4 GROWTH DRIVING FORCES
KEY TRENDS
TABLE 5 KEY TRENDS IN LIQUID BIOPSY
INDUSTRY
TABLE 6 SINGLE CELL ANALYSIS INDUSTRY SUBSECTORS
CHAPTER 4 TECHNOLOGIES
LIQUID BIOPSY BIOMARKERS
TABLE 7 LIQUID BIOPSY BIOMARKER CLASSES
CANCER GENOMICS
FIGURE 1 HOW CANCER GENOMICS DRIVES LIQUID BIOPSY
TABLE 8 SINGLE CELL ANALYSIS TO IDENTIFY CANCER DRIVER MUTATIONS
TABLE 9 GENOMICS-BASED ONCOLOGY WORKFLOW
NONINVASIVE PRENATAL TESTING
TABLE 10 CELL-FREE DNA ANALYSIS APPROACHES
CIRCULATING TUMOR CELL (CTC) TECHNOLOGIES
TABLE 11 UNIQUE TECHNICAL CHALLENGES OF CTC CAPTURE AND ANALYSIS
CTC WORKFLOW
TABLE 12 CTC WORKFLOW
CELL ISOLATION TECHNOLOGIES
TABLE 13 CELL DIFFERENTIATORS
TABLE 14 CELL ISOLATION TECHNOLOGIES
CTC SAMPLE PREPARATION TECHNOLOGIES
TABLE 15 CTC SAMPLE PREPARATION TECHNOLOGIES
CTC DOWNSTREAM ANALYSIS TECHNOLOGIES
TABLE 16 SINGLE CELL ANALYSIS TECHNOLOGIES
COMPARISON OF LIQUID BIOPSY WITH CONVENTIONAL BIOPSY
CANCER TESTING
TABLE 17 ESTIMATED ANNUAL BIOPSY PROCEDURES PERFORMED IN THE U.S. FOR SELECTED CANCERS
TABLE 18 MAIN RISKS FOR NEEDLE-BASED TISSUE BIOPSIES
TABLE 19 FACTORS IN TISSUE BIOPSY
PRENATAL TESTING
TABLE 20 INVASIVE PRENATAL TESTING TECHNOLOGIES
TABLE 21 INVASIVE VERSUS NONINVASIVE PRENATAL TECHNOLOGIES
CHAPTER 5 LIQUID BIOPSY INITIATIVES
KEY COLLABORATIVE INITIATIVES
TABLE 22 KEY LIQUID BIOPSY RESEARCH AND DEVELOPMENT PROGRAMS
CAMBRIDGE SINGLE CELL ANALYSIS CORE FACILITY
CANCER-ID
CTC TRAP CONSORTIUM
EARLY CANCER DETECTION CONSORTIUM
HEMATOLOGIC ONCOLOGY CONSORTIUM
NATIONAL CENTER FOR SINGLE CELL BIOLOGY
PRECISION MEDICINE INITIATIVE
SINGLE CELL ANALYSIS PROGRAM
WORLDWIDE INNOVATIVE NETWORKING (WIN) CONSORTIUM
CHAPTER 6 LIQUID BIOPSY APPLICATIONS
INTRODUCTION
TABLE 23 SOURCE OF FOREIGN BIOMARKERS FOR LIQUID BIOPSY
APPLICATIONS
CANCER APPLICATIONS
PRECISION MEDICINE
TABLE 24 PERSONALIZED MEDICINE DRIVEN BY CANCER COMMON
GENETIC MUTATIONS
CANCER BIOMARKER STATUS
TABLE 25 CANCER LIQUID BIOPSY BIOMARKER CLINICAL STATUS
CANCER MARKET SEGMENTS
TABLE 26 CANCER LIQUID BIOPSY MARKET SEGMENTS
REPRODUCTIVE HEALTH APPLICATIONS
TABLE 27 NIPT AS A SCREENING APPLICATION
TABLE 28 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN
SCREENING
TRANSPLANT DIAGNOSTICS APPLICATIONS
TABLE 29 TRANSPLANT DIAGNOSTICS APPLICATIONS
CHAPTER 7 LIQUID BIOPSY INDUSTRY
INTRODUCTION
TABLE 30 KEY SEGMENTS WITHIN THE LIQUID BIOPSY INDUSTRY
NGS INSTRUMENT INDUSTRY
TABLE 31 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
SUMMARY
DROPLET DIGITAL PCR (DDPCR) INDUSTRY
TABLE 32 ADVANTAGES OF DDPCR FOR SINGLE CELL ANALYSIS
TABLE 33 DDPCR INDUSTRY
TARGET ENRICHMENT AND AMPLIFICATION INDUSTRY
TABLE 34 SINGLE CELL TARGET ENRICHMENT INDUSTRY
SINGLE CELL DNA POLYMERASE INDUSTRY
TABLE 35 SINGLE CELL DNA POLYMERASE INDUSTRY
NONINVASIVE PRENATAL TESTING INDUSTRY
TABLE 36 NGS NIPT INDUSTRY
TABLE 37 GLOBAL NIPT MARKET BY REGION AND COMPANY BY NUMBER OF TESTS, 2015
TABLE 38 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC
COMPANIES, 2015
LIQUID BIOPSY INDUSTRY
TABLE 39 LIQUID BIOPSY INDUSTRY COMPANY FOCUS
CHAPTER 8 ACQUISITIONS AND STRATEGIC ALLIANCES
ACQUISITIONS
TABLE 40 LIQUID BIOPSY INDUSTRY ACQUISITIONS, JANUARY 2013-OCTOBER 2015
STRATEGIC ALLIANCES
TABLE 41 SINGLE CELL INDUSTRY STRATEGIC ALLIANCES, JANUARY 2013-OCTOBER 2015
CHAPTER 9 MARKETS
GROWTH DRIVING FORCES
TABLE 42 LIQUID BIOPSY MARKET GROWTH DRIVING FORCES
LIQUID BIOPSY MARKET
BY INDICATION
TABLE 43 LIQUID BIOPSY MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
BY BIOMARKER TYPE
TABLE 44 LIQUID BIOPSY MARKET BY BIOMARKER TYPE, THROUGH 2020 ($ MILLIONS)
BY ANALYSIS PLATFORM
TABLE 45 LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM, THROUGH 2020 ($ MILLIONS)
BY ANALYSIS PURPOSE
TABLE 46 LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
NONINVASIVE PRENATAL TESTING MARKET
TABLE 47 NIPT MARKET BY RISK TYPE, THROUGH 2020 ($ MILLIONS)
TABLE 48 NIPT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
TABLE 49 NIPT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
TABLE 50 NIPT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
TABLE 51 NGS NIPT MARKET BY INSTRUMENT TYPE, THROUGH 2020 ($ MILLIONS)
CANCER MARKET
TABLE 52 CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
TABLE 53 CANCER MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
TABLE 54 EARLY CANCER DETECTION (MM/NO.)
TABLE 55 CANCER MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
TABLE 56 CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
CTC CANCER MARKET
TABLE 57 CTC CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
TABLE 58 CTC CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
CFDNA CANCER MARKET
TABLE 59 CFDNA CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
TABLE 60 CFDNA CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
EV CANCER MARKET
TABLE 61 EV CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS)
TABLE 62 EV CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
TRANSPLANT MARKET
TABLE 63 TRANSPLANT MARKET BY ORGAN TYPE, THROUGH ($ MILLIONS)
TABLE 64 U.S. LIQUID BIOPSY TRANSPLANT MARKET (PROCEDURES PER YEAR/NUMBER OF PATIENTS)
TABLE 65 TRANSPLANT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS)
TABLE 66 TRANSPLANT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS)
TABLE 67 TRANSPLANT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS)
LIQUID BIOPSY MARKET BY REGION
TABLE 68 LIQUID BIOPSY MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 69 CANCER MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 70 NIPT MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
TABLE 71 TRANSPLANT MARKET BY REGION, THROUGH 2020 ($ MILLIONS)
CHAPTER 10 PATENTS
CIRCULATING TUMOR CELL PATENTS
TABLE 72 CTC PATENTS, 2005-2015
CELL-FREE DNA PATENTS
TABLE 73 CELL-FREE DNA PATENTS, 2005-2015
CHAPTER 11 COMPANY PROFILES
AFFYMETRIX
AGILENT TECHNOLOGIES INC.
ANGLE PLC
ANNOROAD GENE TECHNOLOGY
APOCELL
ASURAGEN INC.
AVIVA BIOSCIENCES
BECTON, DICKINSON AND CO.
BERRY GENOMICS CO. LTD.
BGI SHENZHEN
BIOCARTIS NV
BIOCEPT INC.
BIOFLUIDICA INC.
BIO-RAD LABORATORIES INC.
BOREAL GENOMICS
CELL MICROSYSTEMS INC.
CELLSEE DIAGNOSTICS INC.
CELLULAR RESEARCH INC.
CHRONIX BIOMEDICAL
CIRCULOGENE THERANOSTICS
CIRCULOMICS INC.
CLONTECH LABORATORIES INC.
CYNVENIO BIOSYSTEMS INC.
CYTOTRACK APS
DANAHER CORP.
DIAGNOLOGIX LLC
DNA ELECTRONICS LTD.
EPIC SCIENCES
EXOSOME DIAGNOSTICS INC.
FLUIDIGM CORP.
FOUNDATION MEDICINE
FLUXION BIOSCIENCES INC.
GATC BIOTECH AG
GE HEALTHCARE
GENOMIC HEALTH INC.
GIGAGEN INC.
GOOD START GENETICS INC.
GUARDANT HEALTH INC.
HTG MOLECULAR DIAGNOSTICS INC.
ILLUMINA INC.
TABLE 74 NEW PLATFORMS INTRODUCED BY ILLUMINA, 2015
JOHNSON & JOHNSON
KELLBENX INC.
LABORATORY CORP. OF AMERICA INC.
MDX HEALTH INC.
MERCK KGAA
MYRIAD GENETICS INC.
NATERA INC.
NEOGENOMICS INC.
NEW ENGLAND BIOLABS
NEW ONCOLOGY AG
NUGEN TECHNOLOGIES INC.
OXFORD GENE TECHNOLOGY
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PATHWAY GENOMICS CORP.
PERSONAL GENOME DIAGNOSTICS INC.
PROVISTA DIAGNOSTICS INC.
QIAGEN NV
RAINDANCE TECHNOLOGIES INC.
RARECELLS SAS
RARECYTE INC.
RESOLUTION BIOSCIENCE INC.
ROCHE HOLDING AG
TABLE 75 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING
RUBICON GENOMICS
SALVEO DX
SCREENCELL
SENGENICS INTERNATIONAL PTE LTD.
SEQUENOM INC.
SILICON BIOSYSTEMS
SPHERE FLUIDICS LTD.
STRAND LIFE SCIENCES
STRATEC BIOMEDICAL AG
SYGNIS AG
SYSMEX INOSTICS
TAI DIAGNOSTICS INC.
THERMO FISHER SCIENTIFIC INC.
THORNE DIAGNOSTICS INC.
TROVAGENE INC.
TRANSGENOMIC INC.
VITATEX INC.
WAFERGEN BIO-SYSTEMS INC.
TABLE 76 WAFERGEN STRATEGIC ALLIANCES
XCELL BIOSCIENCES INC.
YIKON GENOMICS CO. LTD.
ZEPHYRUS BIOSCIENCES INC.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report